Clinical Perspectives


Moffitt Studies COVID-19 Vaccine in Oncology Workers

July 15, 2021

AV2A1940 980X510

Moffitt Cancer Center has opened a vital study to assess the immune activation after vaccination for COVID-19 among oncology workers. These workers have a high risk of COVID-19 infection due to their increased contact with a higher number of patients with compromised immune systems who may not have developed immunity against COVID-19.

The world has been faced with an unprecedented pandemic in the magnitude of the number of humans affected, the velocity of spread and in its wide geographical distribution. In late December 2020, the first vaccine was FDA approved and made available for the general population. People around the country lined up to receive their vaccine. However, the clinical efficacy of the COVID-19 vaccine among patients with cancer remains to be determined while healthcare workers both in academic and community centers continue to be in contact with these patients.

This study is asking Florida oncology workers who have been vaccinated and those who have not been vaccinated to participate in this study at Moffitt. Participation will include donating blood and completing questionnaires. The information we learn from the study aims to help better understand measures of immunity against COVID-19 for oncology workers.

For more information about the study or to participate in the study, please email TCC-Coordinators@Moffitt.org

For more information about COVID-19 at Moffitt, please click here.